Rubix LS Rubix Life Sciences
Menu Button

FDA & Clinical Trial Diversity - White Paper

As the life science industry faces even tougher challenges to ensure that patient diversity becomes a center focus for bringing new therapeutics to the market, look at how industry and collaborative partners should concentrate their efforts. Download the latest white paper below. FDA-Clinical-Trial-DiversityDownload

Reginald Swift of Rubix LS Named BBJ Power 50 Movement Maker

Swift along with the other honorees, was recognized for leadership in creating change and taking actionable steps for equity, inclusion, and diverse points of view. Reginald Swift is an innovator and a game-changer who started his biotech company in 2016 with only $600 dollars. With a career that started in...

What Health Informatics Should Be

Health informatics is an interdisciplinary field that uses information technology to organize and analyze health data and knowledge to improve health outcomes.1 Health informatics utilizes resources, devices, and digital methods to acquire, store, retrieve, and use personal health data. A common example is the electronic health record (EHR) that is accessible...

boston-business-journal.png

Rubix LS in the Boston Business Journal

After over a year of helping pharmaceutical companies reach underrepresented patients through its data analytics platform, Lawrence startup Rubix Life Sciences is getting into therapeutics itself. This summer, Rubix announced a new therapeutics division with plans to focus on neurodegenerative and infectious diseases. Now, it's building out a 40,000-square-foot clinical...

Research Lab Facility Rubix LS

Rubix LS of Lawrence Unveils Plan for Clinical Trial Site 300 jobs -40,000 sq ft total Serving The Underrepresented

Local Clinical Research Facility in Lawrence, MassachusettsUnveils Plans to Build Clinical Trial Site for Under-represented Communities Rubix LS unveils a plan for a 40,000 sq. ft site centrally located in Lawrence, Mass.to focus on clinical therapeutic research needs of the under-represented August 16, 2021 (Washington, DC/Lawrence, MA) Rubix LS, a...

Patient Speaking with Doctor

The Language Barrier: Ethnicity and Medicine

In medicine, we're looking at how specificity of language impacts patient behaviors for clinical recommendations. "This is the start of a series of articles we're posting on how dismantling barriers of patient engagement can lead to better outcomes. We're starting our series by discussing communication and language elasticity." The purpose...

African American patient with a doctor for musculoskeletal pain

Therapeutic Outcomes

Health disparities exist among specific population groups in the United States (US) to attain the highest health potential observed by differences in incidence, prevalence, mortality, the burden of disease, and other adverse healthindicators. It is a well-accepted idea that everyone should have a fair and equal opportunity to attain their...

[WHITE PAPER] Clinical Disparities in Disease Diagnosis

Exploring the relationships between clinical disparities in disease diagnosis and patient care and how we build to overcomes these challenges. Rubix LS - Clinical-Disparities-in-Disease-Diagnosis-and-Patient-CareDownload

Rubix LS Launches Therapeutics Division

We're 5 years old! What we've done to date and what we're going to do next.

Rubix LS Closes Seed Round for $1.25M

Funding Campaign Halfway to Goal for StarSense

November 7, 2020, Lawrence, MA - Rubix LS has announced today that it is nearly halfway towards it funding goal of $1M, at $450,000, for its lead platform, StarSense, a virtual clinical trial platform that has been piloted in the utility of patient testing for the infectious diseases under a...

CEO & Founder, Reginald Swift, on Shrimp Tank Podcast.

https://www.youtube.com/watch?v=Ua66XGAVD6M&feature=youtu.be

Rubix LS on Pharma Tech Outlook

Recently our Founder and CEO, Reginald Swift, sat down with the team at Pharma Tech Outlook magazine to discuss the changes happening with the pharma industry and how digital health, particularly virtual clinical trials are mobilizing access of pipeline therapeutics to the world for various disease states. An article to...

Health Data in the COVID-19 Crisis: How racial equity is widening for patients to gain access to treatment.

The coronavirus pandemic has placed extraordinary demands on the healthcare industry and the groups that are interconnected with the healthcare industry. The strain on obtaining adequate resources to establish a baseline of trending symptomatic patients and severity levels is spreading across the country. While many patients who may be exposed...

What we're doing for the COVID-19 crisis...

In the wake of the current COVID-19 crisis plaguing the world, many life science and health technology organizations are mobilizing ways to assist in containing and managing patient symptoms as well as racing toward a vaccine. While the world is approximately 12-18 months away from stemming the tide in the...

Rubix LS Is Supporting The Federal COVID-19 Response.

Rubix LS has joined the federal consortium of industry partners to fully develop plans and strategies for mobilizing robust response measures toward the growing COVID-19 worldwide pandemic in the United States. Rubix LS is joined by countless other firms, within the U.S, to fight against the emerging infectious pathogen that...

Massachusetts Life Science Company Target’s Coronavirus Detection

Rubix LS Successfully Isolated Protein Binding Receptors Previously in Ebola and Leishmaniasis, by Providing Real-Time Rapid Spectral Analysis of Key Proteins, is Actively Adapting Its Technology to Target Coronavirus WASHINGTON - Feb. 2, 2020 -  Rubix LS engineered and deployed rapid diagnostic and elemental detection tools while actively working on studies of Ebola...

Rubix LS Expands with Asset Acquisition of Clinbotics

FOR IMMEDIATE RELEASE Rubix LS Continues 360 Degree Digital Health Campaign To Diversify Health Outcomes A respected leader in the life science and biotech product development and research sectors, Rubix LS has significantly boosted its growing digital healthcare campaign through its recent purchase of the assets of a virtual clinical...

An Interview: Digital Life Sciences & Inclusive Patient Outcomes from the CEO

Recently, the CEO had an opportunity to share his insights with Devin Thorpe, founder of Your Mark on The World, a non-profit group in which the sole mission is: "is to solve the world's biggest problems before 2045 by identifying and championing the work of experts who have created credible plans and...

Rubix LS enters into an agreement to support infectious disease data research

July 17, 2019 - Lawrence, MA - Today, Rubix LS is announcing that they're expanding their virtual clinical trial and disease intelligence platform that will include the nations: Morocco, Kenya, Indonesia and Brazil as part of a wider United Nations, www.un.org, health program for understanding commonalities of disease trends and...

Rubix LS is now an SBA 8a company

[et_pb_section admin_label="section"] [et_pb_row admin_label="row"] [et_pb_column type="4_4"][et_pb_text admin_label="Text"] July 16, 2019, Lawrence, MA - Today, Rubix LS is happy to announce that is reached SBA 8a status. Started in 1942, the SBA 8a program was developed to address vast disparities of economic opportunities, through business encouragement for minorities and key groups...

How IoT Technology is Transforming Healthcare

Technology has changed the way many manufacturers, industrial organizations and utilities operate. The addition of IoT to sensors has expanded their impact and use cases, delivering more connectivity and analytics to processes than ever before. As of today, these smart sensors are internet-enabled and are becoming more sophisticated than ever...

[Infographic] Can Digitalization Save Life on Earth?

As the world contends with new challenges with global warming, one of the threats humankind will be challenged with mitigating are ancient diseases. While 2 new diseases are identified every week, the scale of what we thought we were able to cure may not be as long-gone we once thought...

CRISPR - A genetic revolution or an enormous threat?

It outraged scientists across the globe. Media outlets were stunned. In November 2018, a scientist in China, He Jiankui, reported that he had created the world’s first human babies with CRISPR-edited genes: a pair of twin girls resistant to HIV. The director of the National Institutes of Health, Francis Collins,...

Diversity Alliance For Science Conference

Recently, the founder and CEO, Reginald Swift, had the opportunity to connect with the wider biotech community. As the nature of society is changing toward inclusion for diversity, the life science sector is creating initiatives to do the same for partnering with organizations. Below, Mr. Swift shares his thoughts from...

Rubix LS moves towards a new area of Life Science technology; Digital Life Sciences

February 27, 2019, Lawrence, MA- Life Science company Rubix LS growth has now expanded to encompass a new direction for the organization; Digital Life Sciences. As new tactics to deploy discovery towards patient-centric product development gains momentum, this new direction will refocus Rubix’s core offerings from its R&D expertise towards...

Minorities are under-represented in clinical trials

https://www.facebook.com/208747966176538/posts/766263487091647?sfns=st

Rubix LS Receives 2018 Best of Lawrence Award

Lawrence Award Program Honors the Achievement LAWRENCE, MA December 17, 2018 -- Rubix LS has been selected for 2018 Best of Lawrence Award in the Research and Product Development category by the Lawrence Award Program. Each year, the Lawrence Award Program identifies companies that we believe have achieved exceptional marketing...

Rubix LS announces new Phase II milestone data analysis in lead combination product candidate Project Hercules for targeting osteonecrotic (avascular necrosis) disease

Lawrence, MA - Today, Rubix LS announced the success of a critical milestone within the Phase IIa study of Project Hercules.  Designed as an implantable combination device with wider applications toward targeting osteopenia, arthrodesis and certain malignancies such as onset osteonecrosis, the Phase IIa design study milestone was to incorporate dynamic...

Unpacking the reality of Bioterrorism in 2018

Anthrax. Ebola. Smallpox. These are just a few of the biological agents that could be weaponized for a bioterrorism attack and unlike a bombing or shooting, these microbial agents can incubate for days or weeks going unnoticed until unrelenting illnesses or deaths occur. Bioterrorism became an overwhelming concern after the...

Exploring the Challenges of Clinical Trial Failures

Creating a new drug is undoubtedly harrowing. The success rate of clinical trials is dependent on many factors such as patient enrollment, efficacy, bureaucracy, and awareness of the general public. These concerns are influential factors that ultimately affect which drugs are put on the market. The life sciences industry continues...

The impact of regulatory compliance on life sciences companies

On the quest to push the boundaries of innovation to develop and launch new products, companies have to address an increasing number of regulatory requirements which span multiple geographies, business activities and functions. While the life sciences industry has sustained growth and advances by drafting scalable compliance and business strategies...

Daisy Gallagher As New Senior Board Member of Rubix LS

October 31, 2018, Lawrence, MA - Rubix LS is announcing today veteran business executive and titan, Daisy Gallagher, promoted to the Board of Advisors.  Gallagher is currently Chairman and Founder of Gallagher & Gallagher Worldwide, Inc., Chief Global Strategist, and Senior Executive Advisor, co-founder of SUSTAP LLC, and is an internationally known...

Yunche Wilson, named as new Chief Marketing Officer for Rubix LS

October 29, 2018, Lawrence, MA - Rubix LS is announcing today veteran marketing executive, Yunche Wilson has joined the company as Chief Marketing Officer.  Wilson was most recently Marketing Manager and Director at Cyrus One, an Information Technology company, where she led the business through to an IPO. At Rubix LS,...

Life Sciences industry experiencing hiring challenges due to massive growth

[et_pb_section bb_built="1"][et_pb_row][et_pb_column type="4_4"][et_pb_text _builder_version="3.17.2"] Life sciences companies have always operated in a world of uncertainty. Issues around cost and pricing, clinical and operational innovation, customer and consumer engagement, and regulatory compliance have existed for decades. At the top of the list of challenges, building an organization of the future is...

Rubix LS Launches Data & Research Division

May 8, 2018, Lawrence, MA - Rubix LS is announcing today the launch of its new Data & Research division to its core business function.  This is a step for Rubix LS to strongly position its expertise base to move as a technological think tank. With the addition of its new...

Rubix LS, recognized as recipient of ELSA award

Recognized as an Emerging Life Science Agent. Given to those who have demonstrated significant contribution to advancing unique science and engineering methodologies. April 12, 2018, Lawrence, MA - Rubix LS has been named a Top Innovation Winner in Futuristic Engineering as an Emerging Life Science Agent, honoring best-in-class learning and engineering...

Rubix LS Flies 4D from Prototyping to Now Manufacturing Scale

April 9, 2018, Lawrence, MA - Today Rubix LS announces achievement to scale up ability to achieve manufacturing consistency of 4D printed materials.  It is a manufacturing process that will now incorporate the use of synthetic material intelligence; utilizing both software, fluid mesh, and moldable hardware components to make malleable devices....

Rubix LS is Introducing the I-pprentice Program

March 15, 2018, Lawrence, MA - Rubix LS is happy to announce today a new program in which will serve as a conduit for interested high school and early college students into a new apprenticeship program, aptly called I-pprentice.  It is served to start within the late summer of 2018 and continue...

Rubix LS is Exploring Morocco

medical device firm, today announces that they will be working in tandem with the World Health Organization, to develop mechanisms that can transform some of the ecosystem's natural resources, within countries like Morocco, into disease treatment hubs. "The team here at Rubix LS is obviously excited to be apart of...